Hers vs Wellorithm: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Wellorithm beats Hers overall, scoring 7.4/10 vs 7.3/10. Wellorithm is more affordable at $147/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Wellorithm for cash-pay patients who want compounded semaglutide or tirzepa.
A side-by-side comparison of Hers and Wellorithm covering pricing, scores, medication types, insurance, and more to help you decide.
Hers
#35 of 46The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.
Visit HersWellorithm
#30 of 46Telehealth platform for compounded semaglutide and tirzepatide that uniquely offers BOTH injectable and oral dissolving tablet formats, paired with a 10% weight-loss guarantee that refunds up to four months of program fees if the patient does not lose at least 10% of baseline weight after 16 weeks of medication adherence (terms apply). 28-day recurring billing, non-refundable per-cycle, with a documented address listed in Berlin, Germany.
Visit Wellorithm| Feature | Hers | Wellorithm |
|---|---|---|
| Our Score | 7.3/10 | 7.4/10 |
| Starting Price | $199/mo | $147/mo |
| Medication Type | Both | Compounded |
| Insurance Accepted | No | No |
| Best For | Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand | Cash-pay patients who want compounded semaglutide or tirzepatide with the option of oral dissolving tablets (rare), a 10% weight-loss money-back guarantee, and 24/7 support — and who are comfortable enrolling with a platform that does not publicly disclose its founders, headquarters, or named prescribers |
| Ranking | #35 | #30 |
Pros & Cons Compared
Hers
Pros
- +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services
Cons
- −Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
- −Generic support experience — large patient volume means less personalized attention
- −Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
- −Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value
Wellorithm
Pros
- +Compounded GLP-1 available in BOTH injectable AND oral dissolving tablet formats — semaglutide and tirzepatide each in two formats — broader format menu than most compounded-only platforms
- +10% weight-loss money-back guarantee: patients who don't lose at least 10% of baseline weight after 16 weeks of medication adherence may be eligible for refund of up to four months of program fees (verified weight documentation required)
- +Competitive entry pricing — $147/mo compounded semaglutide and $249/mo compounded tirzepatide put Wellorithm near the cheaper end of the compounded market
- +2-minute qualification quiz, virtual consultation, 24/7 support availability claimed
- +23,000+ reviews and 4.9-star rating reported (volume is unusually high for this market segment — verify on independent third-party sources before relying on it)
- +Spring promotion advertised at $147 with free shipping included
Cons
- −Founding year, corporate ownership, and named prescribers are NOT publicly disclosed — the only address listed is a German one (Berlin, DE 81566), unusual for a platform serving US patients
- −49 states only — service is unavailable in Louisiana and outside the United States
- −28-day recurring billing cycle with payments non-refundable once processed — strict cancellation policy and no proration for partial months
- −Compounded-only — no FDA-approved Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo; FDA does not review compounded medications for safety, effectiveness, or manufacturing quality
- −Weight-loss guarantee terms are restrictive: requires verified weight documentation (doctor attestation or video evidence), prior medication history disclosure, consistent dosing adherence, and refund processed within 30 days of approval — only fees actually paid are refundable, baseline payments remain non-refundable
- −Two different affiliate landing pages (campaign-7 and qoroxapi/lead.php direct route) with different funnel structures suggest the platform tests multiple lead-capture flows, which can create inconsistent post-click experiences
Our Verdict
Wellorithm edges out Hers with a score of 7.4/10 vs 7.3/10. If budget is your priority, Wellorithm starts at $147/mo compared to Hers's $199/mo. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Wellorithm if you want: cash-pay patients who want compounded semaglutide or tirzepatide with the option of oral dissolving tablets (rare), a 10% weight-loss money-back guarantee, and 24/7 support — and who are comfortable enrolling with a platform that does not publicly disclose its founders, headquarters, or named prescribers.